# A Study to Investigate LYL797 in Adults With Solid Tumors

> **NCT05274451** · PHASE1 · TERMINATED · sponsor: **Lyell Immunopharma, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Advanced Breast Cancer
- Advanced Lung Carcinoma
- NSCLC
- NSCLC, Recurrent
- NSCLC Stage IV
- Relapsed Cancer
- Relapse/Recurrence
- Recurrent Breast Cancer
- Recurrent NSCLC
- Platinum-resistant Ovarian Cancer
- Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Endometrial Cancer
- Endometrioid Tumor
- High Grade Serous Carcinoma
- Ovarian Epithelial Cancer

## Interventions

- **BIOLOGICAL:** LYL797

## Key facts

- **NCT ID:** NCT05274451
- **Lead sponsor:** Lyell Immunopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-29
- **Primary completion:** 2024-11-27
- **Final completion:** 2024-11-27
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Pipeline Reprioritization
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05274451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05274451, "A Study to Investigate LYL797 in Adults With Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05274451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*